3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
3
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Melanoma
33
Neoplasms
18
Colorectal Neoplasms
3
Skin Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Solid Tumor
1
Skin Diseases
1
Neoplasms, Unknown Primary
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Cancer Metastatic
1
Biliary Tract Neoplasms
1
Advanced BRAF-mutant Cancers
1
Interventions
Carboplatin
367
Pemetrexed
308
pembrolizumab
302
Cisplatin
242
Paclitaxel
230
Docetaxel
199
Gemcitabine
130
Nivolumab
121
Erlotinib Hydrochloride
114
Bevacizumab
85
osimertinib
78
atezolizumab
65
durvalumab
58
Cetuximab
57
130-nm albumin-bound paclitaxel
56
Gefitinib
52
Ipilimumab
46
Afatinib
38
Drug Therapy
33
Cyclophosphamide
30
Crizotinib
30
Albumin-Bound Paclitaxel
30
Vinorelbine
28
cemiplimab
26
tislelizumab
25
avelumab
23
icotinib
22
Radiotherapy
22
capmatinib
21
Oxaliplatin
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Non-Small-Cell Lung
×
Vemurafenib
×
Clear all
NCT03178552
2026-06-05
B-FAST
Hoffmann-La Roche
Phase 2/3
Active not recruiting
1,000 enrolled
NCT04302025
2026-05-22
NAUTIKA1
Genentech, Inc.
Phase 2
Recruiting
99 enrolled